Failures of Cobalamin Assays in Pernicious Anemia
To the Editor: Cobalamin (vitamin B 12 ) assays have been central to the diagnosis of clinical cobalamin deficiency such as pernicious anemia because the diagnostic sensitivities of older assays have been approximately 95%. 1 However, the competitive-binding luminescence assay (CBLA) replaced older microbiologic and radioisotopedilution assays during the past decade. Few studies have compared these methods, and cobalamin CBLA has received less-focused scrutiny than older methods have received in the past. In 2000, a study showing that a CBLA failed to detect many low cobalamin levels 2 was disputed by the manufacturer. 3 A later article attributed similar failure rates with the same CBLA to the diagnostic insensitivity of cobalamin to clinical cobalamin deficiency, 4 without considering assay error. 5 Since 2006, however, five case reports have identified false normal cobalamin levels in seven patients with pernicious anemia (see the Table in the Sup- plementary Appendix, available with the full text of this letter at NEJM.org), and some authors have proposed that CBLA failure to inactivate serum anti-intrinsic factor antibodies may be responsible. This highly focused, medically serious assay failure easily eludes routine monitoring, and its extent is unknown. Therefore, we examined three questions: How often does CBLA fail in pernicious anemia? Are many CBLAs affected? Is failure linked to the presence of anti-intrinsic factor antibodies in serum? Because serum samples obtained from untreated patients with pernicious anemia are too scarce for meaningful prospective surveys, we used frozen samples obtained 10 to 15 years ago from 23 untreated patients -15 with anti-intrinsic factor antibodies and 8 without them. Each patient met five criteria: a low cobalamin level according to a radioisotope-dilution assay, a sufficient volume of the serum used in the radioisotope-dilution assay for additional testing, a clinically expressed cobalamin deficiency, unequivocal proof of pernicious anemia, and a defined anti-intrinsic factor antibody status. Aliquots were tested in three clinical laboratories with the use of different CBLAs; we accepted each laboratory's reference interval in categorizing the results (see the Supplementary Appendix for all methodologic details).
The three CBLAs showed false normal values in 6 of 23 (26%), 5 of 23 (22%), and 8 of 23 (35%) serum samples, respectively, as compared with a radioisotope-dilution assay (P = 0.03, P = 0.06, and P = 0.02) ( Table 1) . Five serum samples failed with all three CBLAs. False normal results affected 33 to 53% of positive serum samples for antiintrinsic factor antibodies but no serum samples that were negative for anti-intrinsic factor antibodies (P = 0.01 to 0.06). The activity of anti-intrinsic factor antibodies was nonsignificantly greater in the 9 serum samples with a cobalamin assay error than in the 6 without an error (93.7% intrinsic factor-blocking activity vs. 88.5%, P = 0.11). A corrinoid analogue-related assay artifact was ruled out (see the Supplementary Appendix). The study's strengths and limitations are addressed in the Supplementary Appendix.
The diagnostic failures with all three CBLAs This letter was updated on July 26, 2012, at NEJM.org.
